Premium
Hormonal changes with cholesterol reduction: a double‐blind pilot study
Author(s) -
Ormiston T.,
Wolkowitz O. M.,
Reus V. I.,
Johnson R.,
Manfredi F.
Publication year - 2004
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2003.00540.x
Subject(s) - homovanillic acid , medicine , endocrinology , cholesterol , pregnenolone , testosterone (patch) , hormone , dopamine , concomitant , serotonin , steroid , receptor
Summary Background: The lowering of high serum cholesterol levels may be associated with increased non‐cardiac mortality due to behavioral changes, although such endpoints are likely rare. Objective: This current study sought to determine if hormonal changes accompany pharmacologically induced decreases in serum cholesterol levels. Method: Cholesterol, dopamine, homovanillic acid (HVA), serotonin, 5‐HIAA, testosterone, cortisol and pregnenolone were measured at baseline and after 4 weeks of treatment. Results: Subjects’ cholesterol levels significantly declined within 4 weeks. Concomitant significant increase in dopamine and HVA were noted. Conclusion: Although this study is limited in size, it raises the possibility that cholesterol‐lowering drug treatment is associated with hormonal perturbations.